Search

Your search keyword '"O. Grimm"' showing total 399 results

Search Constraints

Start Over You searched for: Author "O. Grimm" Remove constraint Author: "O. Grimm"
399 results on '"O. Grimm"'

Search Results

1. Integrating digital pathology and mathematical modelling to predict spatial biomarker dynamics in cancer immunotherapy

2. FCC Physics Opportunities

3. Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101

5. IO-Synthesise RCC: A pooled analysis of real-world outcomes for advanced renal cell carcinoma patients treated with nivolumab in France and Germany

11. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

14. 1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany

16. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

19. Förderung und Unterstützung der erfolgreichen Ausbildung zum Urologen durch die Deutsche Gesellschaft für Urologie

22. Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the ‘NIMBUS’ phase III clinical trial

23. IO-Synthesise RCC: Real-world outcomes with nivolumab in previously treated advanced renal cell carcinoma, a pooled analysis of patients from France and Germany

24. 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

26. Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER

27. Influence of prostate artery embolization on different qualities of micturition disorders

28. [Risk-adapted therapy for metastatic renal cell carcinoma]

29. HE-LHC: The High-Energy Large Hadron Collider Future Circular Collider Conceptual Design Report Volume 4

30. Risikoadaptierte Therapie des metastasierten Nierenzellkarzinoms

34. Erstlinientherapie des mRCC: ein Update

35. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination

37. Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)

38. Alpharadin-Therapie bei Patienten mit metastasiertem kastrationsrefraktärem Prostatakarzinom

39. Metastasiertes Prostatakarzinom

40. Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

41. 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

42. [Promotion and support of successful training as a urologist by the Deutsche Gesellschaft für Urologie]

43. [Follow-up of renal cell carcinoma in a nonmetastatic stage]

44. Aktueller Stand der Immunonkologie bei urologischen Tumoren

45. Metastasiertes kastrationsresistentes Prostatakarzinom

46. Diagnostik und Therapie retroperitonealer Abszesse

47. Therapiemonitoring und Nebenwirkungsmanagement bei PD-1/PD-L1-Immuncheckpoint-Inhibition

48. Real world data on the use of nivolumab and ipilimumab combination therapy or nivolumab monotherapy in the treatment of renal cell carcinoma: Interim results from the non-interventional study (NIS) NORA

49. Erratum to : An update on renal cell carcinoma

50. T2 Mapping in Prostate Cancer

Catalog

Books, media, physical & digital resources